megestrol / Generic mfg. - LARVOL DELTA

MATRIX: Megestrol Acetate in Improving Neoadjuvant Chemotherapy-Related Weight Loss in Locally Advanced CRC (clinicaltrials.gov) - P3 | N=60 | Recruiting | Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University | Not yet recruiting ➔ Recruiting | Initiation date: Jun 2025 ➔ Nov 2025

Enrollment open • Trial initiation date • Colorectal Cancer • Oncology • Solid Tumor

Low dose olanzapine versus megestrol acetate for treatment of loss of appetite in patients with locally advanced or metastatic gastric, hepato-pancreatico-biliary and lung cancer (ESMO Asia 2025) - "Low dose Olanzapine demonstrated comparable efficacy to Megestrol Acetate in promoting weight gain and appetite in vulnerable cancer patients undergoing chemotherapy. With its favorable tolerability, additional antiemetic utility, convenient once daily dosing and substantial lower cost, low dose Olanzapine may be preferred over Megestrol Acetate for management of CAS in clinical practice."

Clinical • Metastases • Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor

Nano-crystalline megestrol acetate for anorexia-cachexia syndrome in advanced lung cancer (ESMO Asia 2025) - P2 | "The primary endpoint is the proportion of participants with a body weight increase of >5% relative to the baseline. At the same time, the appetite, quality of life, anxiety and depression, relative dose intensity, L3-SMI, and some inflammatory and nutritional indicators will be observed."

Metastases • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

Megestrol acetate in improving neoadjuvant chemotherapy-related weight loss in patients with locally advanced colorectal cancer: A multicenter randomized controlled clinical trial (MATRIX) (ESMO Asia 2025) - P3 | "Pts in the experimental group will receive 6 cycles of NCT regimen of mFOLFOX6 (intravenous oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, 5-fluorouracil 400 mg/m2 and 5-fluorouracil 2400 mg/m2 continuous pumping for 48h) administered every 14 days, in combination with oral MA suspension at a dose of 625 mg/day. A total of 60 pts are planned for enrollment. The study is registered with ClinicalTrials.gov (NCT06998758) and is currently recruiting pts."

Clinical • Metastases • Colorectal Cancer • Oncology • Solid Tumor

Nano-crystalline Megestrol Acetate for Chemotherapy-induced Nausea and Vomiting (clinicaltrials.gov) - P2 | N=127 | Not yet recruiting | Sponsor: AIPING ZHOU

New P2 trial • Chemotherapy-Induced Nausea and Vomiting

Treatment of HRD-positive elderly ovarian cancer patient: a case report. (PubMed, Anticancer Drugs) - "Fluzoparib, the domestically developed PARPi in China, has demonstrated significant efficacy in BRCA-mutated ovarian cancer. In the field of supportive care, megestrol acetate (MA) is recommended as the first-line preferred therapeutic agent for cancer-related anorexia by major guidelines, though its role in first-line ovarian cancer therapy remains unexplored, and evidence for its combination with PARPi is lacking...Imaging assessments revealed significant tumor reduction without disease progression or grade ≥3 adverse events observed throughout follow-up. This case highlights the potential of combining PARPi and hormone therapy as a 'chemotherapy-free' precision treatment model for elderly and HRD-positive ovarian cancer patients, offering a promising strategy to balance efficacy and tolerability in a population traditionally underserved by conventional regimens."

Journal • Anorexia • High Grade Serous Ovarian Cancer • Oncology • Ovarian Cancer • Solid Tumor • BRCA • BRCA2 • HRD

A Study on Nausea and Vomiting Caused by T-DXd in Breast Cancer Patients (clinicaltrials.gov) - P4 | N=120 | Not yet recruiting | Sponsor: Tianjin Medical University Cancer Institute and Hospital

New P4 trial • Breast Cancer • Oncology • Solid Tumor

Neutral red functionalized upconversion nanoparticles as ratiometric luminescence nanoprobes for high sensitively and precisely sensing megestrol acetate in bovine liver. (PubMed, Spectrochim Acta A Mol Biomol Spectrosc) - "The probe had achieved a detection limit of 0.81 μM (S/N = 3) and had performed well in milk, fetal bovine serum, and bovine liver samples. This study had provided a highly specific and environmentally friendly analytical method for the precisely screening of hormone residues in animal-derived foods."

Journal

POLE-mutated atypical endometrial hyperplasia in an adolescent: a 5-year follow-up with LNG-IUS-a case report and literature review. (PubMed, BMC Womens Health) - "Initial treatment with oral megestrol acetate (160 mg/day) for 6 months failed to resolve complex hyperplasia, prompting a transition to a levonorgestrel-releasing intrauterine system (LNG-IUS)...While POLE mutation analysis provided prognostic insights regarding disease behavior, it did not alter the fertility-preserving strategy, which adhered to guideline-based LNG-IUS therapy. Long-term follow-up supports LNG-IUS as a first-line option for adolescent AEH; molecular subtyping may refine risk stratification but requires validation before routine integration."

Journal • Review • Genetic Disorders • Obesity • Polycystic Ovary Syndrome • Women's Health • POLE

A Prospective Real-World Observational Study of Nanocrystalline Megestrol Acetate in Patients With Cancer Cachexia (clinicaltrials.gov) - P4 | N=495 | Recruiting | Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd.

New P4 trial • Real-world evidence • Cachexia • Oncology • Solid Tumor

Topological insights into breast cancer drugs: a QSPR approach using resolving topological indices. (PubMed, Front Chem) - "In this study, we look at the efficacy of numerous breast cancer drugs, including Toremifene, Tucatinib, Ribociclib, Olaparib, Abemaciclib, Anastrozole, Letrozole, Thiotepa, Tamoxifen, and Megestrol Acetate. Furthermore, resolving topological indices examines the relationship between molecular structure and therapeutic effectiveness. The outcomes of these studies help to further our understanding of breast cancer treatments and the development of more focused and customized therapeutics."

Journal • Breast Cancer • Oncology • Solid Tumor

Bortezomib Induced Peripheral and Severe Autonomic Neuropathy Characterized By Dizziness, Orthostatic Hypotension and Weight Loss (ASH 2023) - "B was given in combination with lenalidomide and dexamethasone (VRD) but we feel the neuropathic symptoms are more due to B since the combination of just lenalidomide and dexamethasone is not known to cause such complications...13 of 16 received VRD and 3 received Daratumumab, B and dexamethasone-based induction...Nine patients received appetite stimulants; 2 megestrol and 7 dronabinol...11 of the 16 patients had dizziness; 3 patients received fludrocortisone and one received midodrine...Transplantation without resolution of symptoms could possibly worsen the morbidity and delay post-transplant recovery. To the best of our knowledge, we are the first group to report a series of patients with this symptom complex and strongly feel it requires further study in a larger cohort."

Anorexia • Diabetes • Diabetic Neuropathy • Gastrointestinal Disorder • Hematological Malignancies • Hypotension • Metabolic Disorders • Mucositis • Multiple Myeloma • Nephrology • Neuralgia • Oncology • Orthopedics • Pain • Peripheral Neuropathic Pain • Renal Disease

Nanocrystalline Megestrol Acetate for Cancer-related Fatigue in Advanced Gastric or Colorectal Cancer: A Randomized Controlled Trial [WITHDRAWN] (ESMO 2025) - No abstract available

Clinical • Metastases • Colorectal Cancer • Gastric Cancer • Oncology • Solid Tumor

Fertility-sparing management in early-Stage endometrial cancer: A case-based approach (ESGE 2025) - "Consequently, a levonorgestrel-releasing intrauterine device (LNG-IUD) for local progestin delivery was inserted and systemic hormonal therapy with oral megestrol acetate was continued at a dosage of 160mg daily...The patient is currently under surveillance, with follow-up endometrial biopsies scheduled after 6 months of conservative management to assess the treatment's success. Conclusions This case demonstrates the efficiency of fertility-preserving management in carefully selected patients, further underscoring the value of additional hormonal treatment in achieving regression."

Clinical • CNS Disorders • Endometrial Cancer • Gynecology • Long-acting Reversible Contraceptives • Oncology • Solid Tumor • Women's Health

Case Report: Ovarian endometrioid tumor occurring in a patient with early-stage, low-risk endometrial carcinoma successfully treated by fertility-sparing management. (PubMed, Front Oncol) - "She was diagnosed with stage IA, grade 1 EC managed initially with high-dose oral megestrol acetate followed by a levonorgestrel-releasing intrauterine system due to intolerance...The patient recovered uneventfully and remains under surveillance without adjuvant therapy. This case highlights the rare occurrence of metachronous ovarian endometrioid carcinoma after successful fertility-sparing and hysterectomy, underscores the importance of shared decision-making regarding ovarian preservation, and supports risk-adapted surveillance strategies in this population."

Journal • Endometrial Cancer • Gynecology • Oncology • Ovarian Cancer • Solid Tumor • Women's Health

Enhanced efficacy and safety of combining Aidi injection with megestrol acetate for endometrial cancer treatment. (PubMed, Am J Transl Res) - "Aidi injection combined with MA provided a promising therapeutic strategy for EC. This regimen effectively inhibited tumor progression, improveed quality of life, and decreased serum tumor marker levels (HE4, CEA, and CA125), supporting its potential for broader clinical application."

Journal • Endometrial Cancer • Oncology • Solid Tumor • CEACAM5 • CTGF

Adrenal insufficiency after megestrol acetate for fertility-sparing treatment of endometrial cancer. (PubMed, Gynecol Oncol Rep) - "•AI is a rare yet potentially life-threatening side effect of MA when used for fertility sparing for EC/AH.•The presentation of AI is highly variable and clinicians should employ a low threshold for investigations.•AI can occur while on MA therapy or after abrupt withdrawal; MA should be tapered upon discontinuation.•Patients on MA may require stress dosing at times of surgery/procedures or acute illness.•Consider progestin IUD as a first line therapy, especially in patients with metabolic comorbidities."

Journal • Endocrine Disorders • Endometrial Cancer • Long-acting Reversible Contraceptives • Nephrology • Oncology • Renal Disease • Solid Tumor

Challenges in Fertility Preservation for p53abn Grade 2 Endometrioid Endometrial Cancer: A Case Report and Literature Review. (PubMed, Reprod Sci) - "Her initial treatment involved hysteroscopy-guided resection, hormonal therapy with megestrol acetate (MA), and close monitoring, but the disease recurred within six months...This case underscores the essential role of molecular profiling in clinical decision-making and the need for ongoing research into molecular pathways. Integrating molecular classifiers into routine practice is crucial for improving risk stratification and treatment outcomes, especially in young women pursuing fertility preservation."

Journal • Endometrial Cancer • Genetic Disorders • Gynecologic Cancers • Gynecology • Obesity • Oncology • Solid Tumor • PTEN

Degradation of Typical PPCPs During Anaerobic Digestion and in Soil. (PubMed, Toxics) - "Soil physicochemical properties significantly influenced PPCP degradation rates. Gemfibrozil warrants immediate attention due to its poor degradation; the five PPCPs presenting moderate concern-namely carbamazepine, ciprofloxacin, oxytetracycline, naproxen, and triclosan-require further risk assessment, while sulfamethoxydiazine, megestrol acetate, and progesterone pose low persistence risk according to current evidence."

Journal

A Review on Sarcopenia, Cachexia, and Aging. (PubMed, J Assoc Physicians India) - "The treatment consists of appetite stimulants, dietary and nutritional supplementation, tailored exercise, and anti-inflammatory drugs. Megestrol acetate, an appetite stimulant, and dronabinol (Marinol), a narcotic drug used to treat nausea and vomiting in patients with cachexia."

Journal • Cachexia • Cardiovascular • Chronic Obstructive Pulmonary Disease • Coronary Artery Disease • Immunology • Oncology • Pulmonary Disease • Respiratory Diseases • Sarcopenia

Phase 2 Cachexia Clinical Trial to Evaluate the Efficacy and Safety of ASCA101 (clinicaltrials.gov) - P2 | N=135 | Not yet recruiting | Sponsor: MetaFines

New P2 trial • Cachexia • Oncology • Solid Tumor

Pterostilbene as a promising natural anticancer agent in gynecological cancers. (PubMed, Med Oncol) - "Preclinical studies demonstrate PT's efficacy in reducing tumor size and enhancing anti-tumor activity when pterostilbene (PT) is combined with megestrol acetate (MA)...Further research is needed to fully establish PT's efficacy and safety in gynecological cancer patients. Notably, our literature search did not yield sufficient studies related to vulvar or vaginal cancers, highlighting a significant gap in the current research landscape."

Journal • Review • Cervical Cancer • Endometrial Cancer • Gynecologic Cancers • Oncology • Solid Tumor • Vaginal Cancer • Women's Health

A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015) (clinicaltrials.gov) - P2 | N=250 | Recruiting | Sponsor: Merck Sharp & Dohme LLC | Not yet recruiting ➔ Recruiting | Trial completion date: Jul 2030 ➔ Nov 2027 | Trial primary completion date: Jul 2030 ➔ Nov 2027

Enrollment open • Pan tumor • Trial completion date • Trial primary completion date • Oncology • Solid Tumor

Megestrol Acetate Compared With Megestrol Acetate and Metformin to Prevent Endometrial Cancer (clinicaltrials.gov) - P2 | N=51 | Active, not recruiting | Sponsor: Northwestern University | Recruiting ➔ Active, not recruiting

Enrollment closed • Endometrial Cancer • Oncology • Solid Tumor

Asymptomatic Adrenal Insufficiency Associated With Quetiapine and Megestrol: A Case Report. (PubMed, J Clin Psychopharmacol) - No abstract available

Journal • Endocrine Disorders • Nephrology • Renal Disease